Abstract
The U1snRNA/ribozyme/antisense construct (designated U1/ribozyme) is a chimeric transgene that has proven to be very useful for inhibiting the expression of targeted genes in vitro and in vivo. It consists of a combination of hammerhead ribozyme flanked by target-specific antisense sequences that are in turn flanked by the loops and promoter of U1 snRNA. To construct U1/ribozymes, antisense/ribozyme sequences are first designed corresponding to ribozyme-cleavage consensus “GUC” sequences that are present in the targeted mRNA. Antisense/ribozyme sequences are then inserted between the U1 snRNA loops, and the conceptual secondary structure of the encoded regulatory RNA is analyzed to ensure proper folding. Appropriate antisense/ribozymes are then synthesized as oligonucleotides, annealed, and ligated into the pU1 vector containing the U1 snRNA promoter and loops to yield the pU1/ribozyme expression vector. Constructs can then be transiently or stably expressed in vitro and in vivo to inhibit the expression of target genes. U1/ribozymes can also be expressed in viral vectors for more efficient transfection, or complexed to liposomes for systemic delivery.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abounader, R., Lal, B., Luddy, C., Koe, G., Davidson, B., Rosen, E. M., et al. (2002) In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis. FASEB J. 16(1), 108–110.
Abounader, R., Ranganathan, S., Lal, B., Fielding, K., Book, A., Dietz, H., et al. (1999) Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression. J. Natl. Cancer Inst. 91(18), 1548–1556.
Jiang, W. G., Grimshaw, D., Lane, J., Martin, T. A., Abounader, R., Laterra, J., et al. (2001) A hammerhead ribozyme suppresses expression of HGF/SF receptor, cMET, and reduces migration and invasiveness of breast cancer. Clin. Cancer Res. 7, 2555–2556.
Montgomery, R. A., and Dietz, H. C. (1997) Inhibition of fibrillin 1 expression using U1 snRNA as a vehicle for the presentation of antisense targeting sequence. Hum. Mol. Genet. 4, 519–525.
Guthrie, C. and Patterson, B. (1988).] Spliceosomal snRNAs. Annu. Rev. Genet. 22, 387–419.
Hjalt, T. A. and Wagner, E. G. (1995).] Bulged-out nucleotides protect an antisense RNA from RNase III cleavage. Nucleic Acids Res. 23(4), 571–579.
Fischer, U., Darzynkiewicz, E., Tahara, S. M., Dathan, N. A., Luhrmann, R., and Mattaj, I. W. (1991).] Diversity in the signals required for nuclear accumulation of U snRNPs and variety in the pathways of nuclear transport. J. Cell Biol. 113(4), 705–714.
Hamm, J., Darzynkiewicz, E., Tahara, S. M., and Mattaj, W. I. (1990).] The trimethylguanosine cap structure of U1 snRNA is a component of a bipartite nuclear signal. Cell 62, 569–577.
Zhong, L., Batt, D. B., and Carmichael, G. G. (1994) Targeted nuclear antisense RNA mimics natural antisense-induced degradation of polyoma virus early RNA. Proc. Natl. Acad. Sci. USA 91, 4258–4262.
Carmo-Fonseca, M., Tollervey, D., Pepperkok, R., Barabino, S. M., Merdes, A., Brunner, C., et al. (1991) Mammalian nuclei contain foci which are highly enriched in components of the pre-mRNA splicing machinery. EMBO J. 10(1), 195–206.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Humana Press Inc., Totowa, NJ
About this protocol
Cite this protocol
Abounader, R., Montgomery, R., Dietz, H., Laterra, J. (2004). Design and Expression of Chimeric U1/Ribozyme Transgenes. In: Sioud, M. (eds) Ribozymes and siRNA Protocols. Methods in Molecular Biology™, vol 252. Humana Press. https://doi.org/10.1385/1-59259-746-7:209
Download citation
DOI: https://doi.org/10.1385/1-59259-746-7:209
Publisher Name: Humana Press
Print ISBN: 978-1-58829-226-1
Online ISBN: 978-1-59259-746-8
eBook Packages: Springer Protocols